A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. [electronic resource]
Producer: 20160712Description: 713-9 p. digitalISSN:- 1791-7530
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- administration & dosage
- Drug Administration Schedule
- Drug Resistance, Neoplasm
- Everolimus -- therapeutic use
- Female
- Humans
- Imidazoles -- administration & dosage
- Male
- Middle Aged
- Neuroendocrine Tumors -- drug therapy
- Pancreatic Neoplasms -- drug therapy
- Phosphatidylinositol 3-Kinase -- metabolism
- Phosphoinositide-3 Kinase Inhibitors
- Prospective Studies
- Protein Kinase Inhibitors -- administration & dosage
- Quinolines -- administration & dosage
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.